[218 Pages Report] The organ preservation market is projected to reach USD 317 million by 2026 from USD 230 million in 2021, at a CAGR of 6.6%. Growth in this market is majorly driven by the increasing incidence of multi-organ failure, the growing geriatric population, the rising number of organ transplants and organ donors, and increasing initiatives to encourage organ donations.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. The pandemic has disrupted healthcare systems worldwide, with hospitals being overwhelmed due to the increasing influx of patients. Temporary hospitals were also set up to deal with the growing number of cases. The coronavirus disease has had an impact on all facets of healthcare, including the execution of life-saving procedures like organ transplantation by altering the process of organ donation and recovery. The spread of COVID-19 has profoundly impacted organ donation and transplantation worldwide. It has disrupted these actions and significantly reduced donation and transplant activities across the globe, leading to a decline in the demand for organ preservation products. In many countries, transplants from deceased donors were limited to only urgent situations and transplants from living donations were put on hold during the period of the outbreak. This resulted in lost opportunities for a large number of vulnerable patients on transplant waiting lists. The pandemic has also resulted in a decrease in the number of potential deceased organ donors, saturation of healthcare systems and ICU capacities, limited access to donor and recipient testing for the infection, and challenges in travel/transport logistics for retrieval teams and donated organs.
Multiple organ failure is among the most common causes of death in ICUs, mainly caused by sepsis. It is estimated that 26–50% of patients diagnosed with sepsis develop acute renal failure, and up to 20% show acute respiratory failure (Source: Society of Critical Care Medicine). The elderly are at a higher risk of acute renal failure due to an age-related decline in the glomerular filtration rate and the renal plasma flow.
Diabetes also increases the vulnerability to these conditions and multiple organ failure. Diseases such as tuberculosis and liver cirrhosis are more common among geriatric individuals and may make it necessary for individuals to undergo organ transplants.
According to the Organ Procurement and Transplantation Network, the growth of the geriatric population has a large impact on the number of organ transplantation procedures carried out, as the number of older people receiving organ transplants has grown. For instance, the US observed an increase in the number of organ transplants in the above-65 age group—from 8,691 in 2019 to 8,895 in 2021. As per the UN World Population Ageing Report, there were 728 million people aged 65 years or more globally in 2020; this is expected to cross 1.5 billion by 2050, which indicates the potential for demand growth. As a result, the growth in this population segment, given its high susceptibility to conditions causing organ failure, will be a key driver of market growth (Source: UN Department of Economic and Social Affairs).
Organ transplantation is a resource-intensive procedure involving highly paid doctors and surgeons, expensive transportation, and pricey drugs that make it expensive. The charges associated with inpatient care, organ procurement, preservation, post-operative recipient care, and anti-rejection medication increase the overall cost. Patients also need to incur additional costs of traveling, lodging, meals, hospital visits, and other medical testing expenditures for evaluation or follow-ups scheduled at the transplant center for an advised time period of medical supervision. For low-income patients, such expenses directly compete with expenditure on necessities such as food, clothing, and shelter, which often renders organ transplantation procedures inaccessible without external aid. Organ transplantation is highly inequitable, but governments could promote more low-cost interventions or provide financial aid for high-cost surgeries, especially for low-income patients. Thus, the high cost of transplant procedures is one of the major factors restricting the growth of the organ preservation market. However, the cost of organ transplants performed in China and India is comparatively lower than in developed nations, encouraging medical tourism to these countries.
Governments across the globe are focusing on strengthening their healthcare infrastructures to provide enhanced healthcare facilities. For example, in India, the Brihanmumbai Municipal Corporation allocated nearly USD 924 million (INR 7,000 crore) or 15% of its 2022–2023 budget to upgrade health services and establish 100 health centers with more than 100 diagnostic tests for preventive and primary treatment in BMC areas. These infrastructural developments will lead to an increased number of hospitals that treat more brain-dead patients who might be suitable donors. The increasing number of testing laboratories will also improve the time concerned with donor-recipient cross-matching, subject profiling, genotyping, and other related diagnostic tests during the pre-transplantation period. These developments are expected to create new opportunities for the organ preservation market.
Currently, there is a significant gap between the number of organs donated and the number of organs required. In the US, the total number of patients on the waiting list for organs was over 100,000 (106,588 as of January 2022). Only 41,354 transplants were performed by the end of 2021 (Source: Organ Procurement and Transplantation Network, US). The limited number of organs donated annually is mainly due to a lack of awareness related to organ donation, poor legislative measures, and the increased risk of organ trafficking. Governments of various countries are also implementing reformed laws (such as opt-out laws that presume every citizen is an organ donor except for some exempted conditions) and initiatives to encourage people to donate organs.
Based on solution, the organ preservation market is segmented into UW Solution, Custodial HTK, Perfadex and Other solutions (EuroCollins and Celsior). The UW solution segment holds the highest share in 2020. This solution is applicable for the flushing and storage of kidneys, liver, and pancreas. It was the first intracellular preservation medium and is considered the gold standard for organ preservation. The large share of this segment can be attributed to the increased adoption of UW solution due to presence of metabolically inert substrates, such as lactobionate and raffinose, which enable better transplantation outcomes, less histological damage, and improved physiological function of organs compared to other solutions.
Based on technique, the market is divided into static cold storage, hypothermic machine perfusion and normothermic machine perfusion. The static cold storage segment accounted for the largest share of the organ preservation market in 2020. This is the conventional method which is highly adopted and considered as the gold standard technique for organ preservation as the hypothermia induced in this technique results in reduced kinetics of metabolic activities from the donor organ. This technique is used to preserve the kidneys, liver, lungs, pancreas, and heart.
Based on organ type, the organ preservation market has been divided into kidney, liver, lung, heart and pancreas. In 2020, the kidney segment accounted for the largest share of the organ preservation market. This can be attributed to the escalating cases of ESRD with kidney transplantation as the suggestive line of therapeutic treatment that will increase the number of kidney transplant procedures leading to the preservation of the donor’s kidney before its transplantation into the recipient.
Based on end user, the organ preservation market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment accounted for the largest share of the organ preservation market in 2020. The increasing number of transplant centers across the globe is the key factor driving the acceptance of this end-user segment and propelling the market growth.
In 2020, North America accounted for the largest share of the organ preservation market, followed by the Asia Pacific, Europe, Latin America, and the Middle East & Africa. The large share of this region can be attributed to factors such as the growing demand for and adoption of organ transplantation as a result of the rising number of chronic diseases such as end-stage diseases. The need for preservation solutions to protect the viability of organs in ex-vivo environments in the region is also a key factor contributing to the large share of North America in the organ preservation market.
To know about the assumptions considered for the study, download the pdf brochure
The prominent players in the organ preservation market include Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr. Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Shanghai Genext Medical Technology (China), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut Georges Lopez (France), Global Transplant Solutions (US), Avionord (Italy), Organ Preservation Solutions (England), EBERS (Spain), S.A.L.F. (Italy), Biochefa (Poland), Vascular Perfusion Solutions (US), and TX Innovations (Netherlands).
Report Metric |
Details |
Market size available for years |
2019–2026 |
Base year considered |
2020 |
Forecast period |
2021–2026 |
Forecast units |
Value (USD) |
Segments covered |
Solution, Technique, Organ Type, and End-user |
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa |
Companies covered |
Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr. Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Shanghai Genext Medical Technology (China), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut Georges Lopez (France), Global Transplant Solutions (US), Avionord (Italy), Organ Preservation Solutions (England), EBERS (Spain), S.A.L.F. (Italy), Biochefa (Poland), Vascular Perfusion Solutions (US), and TX Innovations (Netherlands). |
The study categories the Organ Preservation Market based on solution, technique, organ type, end user, and regional and global level.
Which are the top industry players in the global organ preservation market?
The top market players in the global organ preservation market include Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr. Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Shanghai Genext Medical Technology (China), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut Georges Lopez (France), and Global Transplant Solutions (US).
Which global organ preservation solutions have been included in this report?
This report contains the following main segments:
Which geographical region is dominating in the global organ preservation market?
The global organ preservation market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounted for the largest share of the organ preservation market, followed by the Asia Pacific, Europe, Latin America, and the Middle East & Africa. North America has the larger share in the organ preservation market, which is attributed to factors such as the growing demand for and adoption of organ transplantation as a result of the rising number of chronic diseases such as end-stage diseases. The need for preservation solutions to protect the viability of organs in ex-vivo environments in the region is also a key factor contributing to the large share of North America in the organ preservation market. The presence of a large number of players in the region is also a key factor contributing to the large share of North America in the organ preservation market. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 29)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.2.2 MARKET SEGMENTATION
FIGURE 1 ORGAN PRESERVATION MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
1.4 STAKEHOLDERS
1.5 LIMITATIONS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 34)
2.1 RESEARCH APPROACH
2.2 RESEARCH METHODOLOGY DESIGN
FIGURE 2 ORGAN PRESERVATION MARKET: RESEARCH DESIGN
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.2.2.1 Key data from primary sources
2.2.2.2 Insights from primary experts
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION: ORGAN PRESERVATION MARKET
FIGURE 6 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 7 ILLUSTRATIVE EXAMPLE OF PROCEDURE-BASED MARKET ESTIMATION
FIGURE 8 TOP-DOWN APPROACH
FIGURE 9 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ORGAN PRESERVATION MARKET (2021–2026)
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.5 MARKET RANKING ANALYSIS
2.6 ASSUMPTIONS FOR THE STUDY
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: ORGAN PRESERVATION MARKET
3 EXECUTIVE SUMMARY (Page No. - 48)
FIGURE 12 ORGAN PRESERVATION MARKET, BY SOLUTION, 2021 VS. 2026 (USD MILLION)
FIGURE 13 ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2021 VS. 2026 (USD MILLION)
FIGURE 14 ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 15 ORGAN PRESERVATION MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 16 GEOGRAPHIC ANALYSIS: ORGAN PRESERVATION MARKET
4 PREMIUM INSIGHTS (Page No. - 52)
4.1 ORGAN PRESERVATION MARKET OVERVIEW
FIGURE 17 RISING NUMBER OF SOLID ORGAN TRANSPLANTS TO DRIVE GROWTH IN THE GLOBAL ORGAN PRESERVATION MARKET 52
4.2 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY SOLUTION & COUNTRY
FIGURE 18 THE UNIVERSITY OF WISCONSIN SOLUTION SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC ORGAN PRESERVATION SOLUTIONS MARKET IN 2020
4.3 ORGAN PRESERVATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 CHINA IS EXPECTED TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 54
4.4 ORGAN PRESERVATION MARKET, BY REGION (2019–2026)
FIGURE 20 NORTH AMERICA TO DOMINATE THE ORGAN PRESERVATION MARKET TILL 2026
4.5 ORGAN PRESERVATION MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD 55
5 MARKET OVERVIEW (Page No. - 56)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
TABLE 3 MARKET DYNAMICS: ORGAN PRESERVATION MARKET
5.2.1 DRIVERS
5.2.1.1 Growing geriatric population and subsequent growth in cases of multiple organ failure
TABLE 4 GROWTH IN GERIATRIC POPULATION (ABOVE-65 AGE GROUP), BY REGION, 2019 VS. 2050 (MILLION)
5.2.1.2 Increasing initiatives to promote public awareness and encourage organ donation
5.2.1.3 Rising number of organ donors and growing adoption of solid organ transplantation procedures
TABLE 5 NUMBER OF ORGAN DONATIONS, 2020
5.2.2 RESTRAINTS
5.2.2.1 High cost of organ transplantation
5.2.2.2 Religious concerns and misconceptions associated with organ donation
5.2.3 OPPORTUNITIES
5.2.3.1 Growing healthcare investments
5.2.4 CHALLENGES
5.2.4.1 Significant gap between the number of organs donated and organs required annually
5.2.4.2 Development of artificial organs
5.3 INDUSTRY TRENDS
5.3.1 SINGLE-PORT ROBOT-ASSISTED KIDNEY TRANSPLANT
5.3.2 PIG-TO-HUMAN XENOTRANSPLANTATION
5.4 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 PORTER’S FIVE FORCES ANALYSIS
5.4.1 THREAT FROM NEW ENTRANTS
5.4.2 THREAT FROM SUBSTITUTES
5.4.3 BARGAINING POWER OF SUPPLIERS
5.4.4 BARGAINING POWER OF BUYERS
5.4.5 INTENSITY OF COMPETITIVE RIVALRY
5.5 PRICING ANALYSIS
TABLE 7 AVERAGE SELLING PRICE OF ORGAN PRESERVATION BY SOLUTION AND BY ORGANS
5.6 ECOSYSTEM ANALYSIS
FIGURE 22 ORGAN PRESERVATION MARKET: ECOSYSTEM ANALYSIS
5.7 VALUE CHAIN ANALYSIS
FIGURE 23 ORGAN PRESERVATION MARKET: VALUE CHAIN ANALYSIS
5.8 PATENT ANALYSIS
5.8.1 PATENT PUBLICATION TRENDS FOR ORGAN PRESERVATION
FIGURE 24 PATENT PUBLICATION TRENDS (2011–2022)
5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 25 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR ORGAN PRESERVATION PATENTS (JANUARY 2011–FEBRUARY 2022)
FIGURE 26 TOP APPLICANT COUNTRIES/REGIONS FOR ORGAN PRESERVATION PATENTS (JANUARY 2011–FEBRUARY 2022)
TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN THE ORGAN PRESERVATION MARKET, 2020–2021
5.9 REGULATORY LANDSCAPE
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.10 IMPACT OF COVID-19 ON THE ORGAN PRESERVATION MARKET
6 ORGAN PRESERVATION MARKET, BY SOLUTION (Page No. - 73)
6.1 INTRODUCTION
TABLE 9 ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 10 ORGAN PRESERVATION SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.2 UNIVERSITY OF WISCONSIN
6.2.1 UW SOLUTIONS COMPRISE METABOLICALLY INERT SUBSTRATES, WHICH ENABLE BETTER TRANSPLANTATION OUTCOMES—A KEY FACTOR DRIVING MARKET GROWTH
TABLE 11 ORGAN PRESERVATION MARKET FOR UW SOLUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 CUSTODIOL HTK
6.3.1 DESPITE ITS LOW COST AND EASY DIFFUSION, THE DEMAND FOR HTK HAS DECLINED IN RECENT YEARS—A KEY FACTOR LIMITING MARKET GROWTH
TABLE 12 ORGAN PRESERVATION MARKET FOR CUSTODIOL HTK SOLUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
6.4 PERFADEX
6.4.1 LAUNCH OF PERFADEX PLUS TO DRIVE MARKET GROWTH
TABLE 13 ORGAN PRESERVATION MARKET FOR PERFADEX SOLUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
6.5 OTHER SOLUTIONS
TABLE 14 OTHER ORGAN PRESERVATION SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 ORGAN PRESERVATION MARKET, BY TECHNIQUE (Page No. - 80)
7.1 INTRODUCTION
TABLE 15 COMPARISON OF THE METHODS USED FOR ORGAN PRESERVATION
TABLE 16 ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 17 ORGAN PRESERVATION TECHNIQUES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.2 STATIC COLD STORAGE
7.2.1 STATIC COLD STORAGE IS THE MOST WIDELY ADOPTED METHOD— A KEY FACTOR DRIVING MARKET GROWTH
TABLE 18 STATIC COLD STORAGE: ADVANTAGES & DISADVANTAGES
TABLE 19 ORGAN PRESERVATION MARKET FOR STATIC COLD STORAGE, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 HYPOTHERMIC MACHINE PERFUSION
7.3.1 ADVANTAGES ASSOCIATED WITH HYPOTHERMIC MACHINE PERFUSION, SUCH AS ENHANCED ORGAN PRESERVATION QUALITY AND SURVIVAL RATE, TO DRIVE MARKET GROWTH
TABLE 20 HYPOTHERMIC MACHINE PERFUSION: ADVANTAGES & DISADVANTAGES
TABLE 21 ORGAN PRESERVATION MARKET FOR HYPOTHERMIC MACHINE PERFUSION, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 NORMOTHERMIC MACHINE PERFUSION
7.4.1 TECHNOLOGICAL DEVELOPMENTS AND ADVANTAGES OF NORMOTHERMIC MACHINE PERFUSION TO DRIVE MARKET GROWTH
TABLE 22 NORMOTHERMIC MACHINE PERFUSION: ADVANTAGES & DISADVANTAGES
TABLE 23 ORGAN PRESERVATION MARKET FOR NORMOTHERMIC MACHINE PERFUSION, BY COUNTRY, 2019–2026 (USD MILLION)
8 ORGAN PRESERVATION MARKET, BY ORGAN TYPE (Page No. - 87)
8.1 INTRODUCTION
FIGURE 27 NUMBER OF ORGAN TRANSPLANTS GLOBALLY, 2020
TABLE 24 ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
8.2 KIDNEYS
8.2.1 KIDNEYS ARE THE MOST TRANSPLANTED ORGANS GLOBALLY—A KEY FACTOR DRIVING MARKET GROWTH
TABLE 25 NUMBER OF KIDNEY TRANSPLANTS IN MAJOR COUNTRIES, 2017–2020
TABLE 26 TOTAL KIDNEY TRANSPLANT CENTERS IN MAJOR COUNTRIES, 2019 VS. 2020
FIGURE 28 US: NUMBER OF ESRD PATIENTS ADDED TO THE WAITING LIST FOR KIDNEY TRANSPLANTS, 2000–2018
FIGURE 29 US: COUNT AND RATE OF KIDNEY TRANSPLANTS IN PATIENTS UNDERGOING DIALYSIS, 2000–2018
TABLE 27 KIDNEY PRESERVATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 LIVER
8.3.1 RISING PREVALENCE OF LIVER DISEASE AND GROWING CASES OF LIVER FAILURE TO DRIVE THE DEMAND FOR LIVER TRANSPLANTATION PROCEDURES
TABLE 28 NUMBER OF LIVER TRANSPLANTS IN MAJOR COUNTRIES, 2017–2020
TABLE 29 TOTAL LIVER TRANSPLANT CENTERS IN MAJOR COUNTRIES, 2019 VS. 2020
TABLE 30 LIVER PRESERVATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 LUNGS
8.4.1 GROWTH IN COPD INCIDENCE BOOSTS THE DEMAND FOR PRESERVATION TECHNIQUES AND PRODUCTS
TABLE 31 US: PREVALENCE OF COPD CASES IN MAJOR STATES, BY GENDER, 2018
TABLE 32 NUMBER OF LUNG TRANSPLANTS IN MAJOR COUNTRIES, 2017–2020
TABLE 33 TOTAL LUNG TRANSPLANT CENTERS IN MAJOR COUNTRIES, 2019 VS. 2020
TABLE 34 LUNG PRESERVATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 HEART
8.5.1 ADVANCEMENTS IN HEART PRESERVATION TECHNIQUES TO DRIVE MARKET GROWTH
TABLE 35 NUMBER OF HEART TRANSPLANTS IN MAJOR COUNTRIES, 2017–2020
TABLE 36 TOTAL HEART TRANSPLANT CENTERS IN MAJOR COUNTRIES, 2019 VS. 2020
TABLE 37 HEART PRESERVATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 PANCREAS
8.6.1 GROWING PREVALENCE OF DIABETES TO DRIVE MARKET GROWTH
TABLE 38 NUMBER OF PANCREAS TRANSPLANTS IN MAJOR COUNTRIES, 2017–2020
TABLE 39 TOTAL PANCREAS TRANSPLANT CENTERS IN MAJOR COUNTRIES, 2019 VS. 2020
TABLE 40 PANCREAS PRESERVATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
9 ORGAN PRESERVATION MARKET, BY END USER (Page No. - 101)
9.1 INTRODUCTION
TABLE 41 ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 ORGAN TRANSPLANT CENTERS
9.2.1 ORGAN TRANSPLANT CENTERS ARE THE MAJOR END USERS OF ORGAN PRESERVATION SOLUTIONS
FIGURE 30 NUMBER OF ORGAN TRANSPLANT CENTERS, 2019 VS. 2020
TABLE 42 ORGAN PRESERVATION MARKET FOR ORGAN TRANSPLANT CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 HOSPITALS
9.3.1 INCREASING INCIDENCE OF ACCIDENTAL INJURIES AND CHRONIC DISEASES TO DRIVE MARKET GROWTH
TABLE 43 ORGAN PRESERVATION MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 SPECIALTY CLINICS
9.4.1 INCREASING PREVALENCE OF END-STAGE DISEASES AND ORGAN FAILURE TO DRIVE MARKET GROWTH
TABLE 44 ORGAN PRESERVATION MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)
10 ORGAN PRESERVATION MARKET, BY REGION (Page No. - 107)
10.1 INTRODUCTION
FIGURE 31 CHINA IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE ORGAN PRESERVATION MARKET
FIGURE 32 TOTAL NUMBER OF ORGAN TRANSPLANTS IN SOME COUNTRIES, 2019 VS. 2020
TABLE 45 ORGAN PRESERVATION MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 33 NORTH AMERICA: ORGAN PRESERVATION MARKET SNAPSHOT
TABLE 46 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 47 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 48 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 49 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 50 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 Growing cases of organ failure and underlining diseases to drive the demand for organ transplantation in the US 114
TABLE 51 NUMBER OF ORGAN TRANSPLANTS IN THE US, 2017–2020
TABLE 52 WAITING LIST FOR ORGAN TRANSPLANTS (AS OF JANUARY 2022)
FIGURE 34 US: NUMBER OF ORGAN TRANSPLANT CENTERS, 2019 VS. 2020
TABLE 53 US: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 54 US: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 55 US: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 56 US: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Improved organ donation rates to drive growth in the market
in Canada 117
TABLE 57 CANADA: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
FIGURE 35 CANADA: NUMBER OF ORGAN TRANSPLANT CENTERS, 2020
TABLE 58 ACTIVE WAITING LIST FOR ORGAN TRANSPLANTS, 2019
TABLE 59 CANADA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 60 CANADA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 61 CANADA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 62 CANADA: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 63 EUROPE: ORGAN PRESERVATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 64 EUROPE: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 65 EUROPE: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 66 EUROPE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 67 EUROPE: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 FRANCE
10.3.1.1 Increasing number of organ transplants and organ donor registrations promote future growth of the organ preservation market in France
TABLE 68 FRANCE: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
FIGURE 36 FRANCE: NUMBER OF ORGAN TRANSPLANT CENTERS, 2019 VS. 2020
TABLE 69 FRANCE: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 70 FRANCE: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 71 FRANCE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 72 FRANCE: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 SPAIN
10.3.2.1 Spain registered the second-highest deceased organ donation rate globally—a key factor driving market growth
TABLE 73 SPAIN: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
TABLE 74 SPAIN: TOTAL NUMBER OF PATIENTS ON THE ORGAN TRANSPLANT WAITING LIST, 2017–2019
FIGURE 37 SPAIN: NUMBER OF ORGAN TRANSPLANT CENTERS, 2020
TABLE 75 SPAIN: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 76 SPAIN: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 77 SPAIN: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 78 SPAIN: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 UK
10.3.3.1 Growth in the market in the UK is mainly driven by the increasing disease/disorder prevalence and favorable regulations
TABLE 79 UK: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
TABLE 80 UK: TOTAL NUMBER OF PATIENTS ON THE ACTIVE ORGAN TRANSPLANT WAITING LIST (AS OF APRIL 8, 2021)
FIGURE 38 UK: NUMBER OF ORGAN TRANSPLANT CENTERS, 2020
TABLE 81 UK: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 82 UK: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 83 UK: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 84 UK: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Declining rate of organ donation and transplant due to COVID-19 limited market growth in 2020
TABLE 85 ITALY: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
TABLE 86 ITALY: TOTAL NUMBER OF PATIENTS ON THE ORGAN TRANSPLANT WAITING LIST, 2020
FIGURE 39 ITALY: NUMBER OF ORGAN TRANSPLANT CENTERS, 2019 VS. 2020
TABLE 87 ITALY: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 88 ITALY: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 89 ITALY: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 90 ITALY: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.5 GERMANY
10.3.5.1 Low organ donation and transplant rates form a major concern for the German market
TABLE 91 GERMANY: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
TABLE 92 GERMANY: TOTAL NUMBER OF PATIENTS ACTIVE ON THE ORGAN TRANSPLANT WAITING LIST, 2019–2021
FIGURE 40 GERMANY: NUMBER OF ORGAN TRANSPLANT CENTERS, 2019 VS. 2020
TABLE 93 GERMANY: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 94 GERMANY: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 95 GERMANY: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 96 GERMANY: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 97 ROE: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 98 ROE: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 99 ROE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 100 ROE: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 41 ASIA PACIFIC: ORGAN PRESERVATION MARKET SNAPSHOT
TABLE 101 APAC: ORGAN PRESERVATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 102 APAC: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 103 APAC: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 104 APAC: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 105 APAC: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Growing awareness and adoption of laws favoring organ donation to drive market growth in China
TABLE 106 CHINA: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
FIGURE 42 CHINA: NUMBER OF ORGAN TRANSPLANT CENTERS, 2019 VS. 2020
TABLE 107 CHINA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 108 CHINA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 109 CHINA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 110 CHINA: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.2 INDIA
10.4.2.1 Lack of awareness is a key barrier to market growth in India
FIGURE 43 INDIA: NUMBER OF ORGAN TRANSPLANT CENTERS, 2019 VS. 2020
TABLE 111 INDIA: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
TABLE 112 INDIA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 113 INDIA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 114 INDIA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 115 INDIA: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Religious beliefs and lack of awareness limit market growth in Japan
TABLE 116 JAPAN: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
TABLE 117 JAPAN: TOTAL NUMBER OF PATIENTS ON THE ORGAN TRANSPLANT WAITING LIST (AS OF MARCH 31, 2021)
FIGURE 44 JAPAN: NUMBER OF ORGAN TRANSPLANT CENTERS, 2019 VS. 2020
TABLE 118 JAPAN: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 119 JAPAN: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 120 JAPAN: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 121 JAPAN: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 122 ROAPAC: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 123 ROAPAC: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 124 ROAPAC: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 125 ROAPAC: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 IMPLEMENTATION OF EDUCATIONAL PROGRAMS TO TRAIN PROFESSIONALS ON ORGAN RETRIEVAL AND TRANSPLANT PROCEDURES TO DRIVE MARKET GROWTH
TABLE 126 BRAZIL: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
FIGURE 45 BRAZIL: NUMBER OF ORGAN TRANSPLANT CENTERS, 2019 VS. 2020
TABLE 127 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 128 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 129 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 130 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 IMPLEMENTATION OF GOVERNMENT INITIATIVES AND POLICIES TO DRIVE MARKET GROWTH
TABLE 131 SAUDI ARABIA: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
TABLE 132 ISRAEL: NUMBER OF ORGAN TRANSPLANTS, 2017–2020
TABLE 133 UAE: NUMBER OF ORGAN TRANSPLANTS, 2018–2020
TABLE 134 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
TABLE 135 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2019–2026 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2019–2026 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY END USER, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 160)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE ORGAN PRESERVATION MARKET
11.3 MARKET RANKING ANALYSIS
TABLE 138 ORGAN PRESERVATION MARKET RANKING ANALYSIS, BY KEY PLAYER, 2020
11.4 COMPETITIVE BENCHMARKING
11.4.1 FOOTPRINT OF COMPANIES IN THE ORGAN PRESERVATION MARKET
TABLE 139 COMPANY ORGAN PRESERVATION SOLUTION & DEVICE FOOTPRINT
TABLE 140 COMPANY TECHNIQUE FOOTPRINT
TABLE 141 COMPANY REGIONAL FOOTPRINT
11.5 COMPETITIVE LEADERSHIP MAPPING
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 46 ORGAN PRESERVATION MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
11.6 COMPETITIVE SCENARIO
11.6.1 PRODUCT LAUNCHES & APPROVALS
TABLE 142 PRODUCT LAUNCHES & APPROVALS, 2018–2022
11.6.2 DEALS
TABLE 143 DEALS, 2018–2022
11.6.3 OTHER DEVELOPMENTS
TABLE 144 OTHER DEVELOPMENTS, 2018–2022
12 COMPANY PROFILES (Page No. - 173)
12.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 PARAGONIX TECHNOLOGIES, INC.
TABLE 145 PARAGONIX TECHNOLOGIES, INC.: BUSINESS OVERVIEW
12.1.2 XVIVO PERFUSION AB
TABLE 146 XVIVO PERFUSION AB: BUSINESS OVERVIEW
FIGURE 47 XVIVO PERFUSION AB: COMPANY SNAPSHOT (2020)
12.1.3 DR. FRANZ KÖHLER CHEMIE GMBH
TABLE 147 DR. FRANZ KÖHLER CHEMIE GMBH: BUSINESS OVERVIEW
12.1.4 ESSENTIAL PHARMACEUTICALS, LLC (A SUBSIDIARY OF ACCORD HEALTHCARE)
TABLE 148 ESSENTIAL PHARMACEUTICALS, LLC: BUSINESS OVERVIEW
12.1.5 TRANSMEDICS, INC.
TABLE 149 TRANSMEDICS, INC.: BUSINESS OVERVIEW
12.1.6 ORGANOX LIMITED
TABLE 150 ORGANOX LIMITED: BUSINESS OVERVIEW
12.1.7 21ST CENTURY MEDICINE
TABLE 151 21ST CENTURY MEDICINE: BUSINESS OVERVIEW
12.1.8 SHANGHAI GENEXT MEDICAL TECHNOLOGY CO., LTD.
TABLE 152 SHANGHAI GENEXT MEDICAL TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
12.1.9 BRIDGE TO LIFE LIMITED
TABLE 153 BRIDGE TO LIFE LIMITED: BUSINESS OVERVIEW
12.1.10 WATERS MEDICAL SYSTEMS LLC
TABLE 154 WATERS MEDICAL SYSTEMS: BUSINESS OVERVIEW
12.1.11 PRESERVATION SOLUTIONS, INC.
TABLE 155 PRESERVATION SOLUTIONS, INC.: BUSINESS OVERVIEW
12.1.12 CARNAMEDICA
TABLE 156 CARNAMEDICA: BUSINESS OVERVIEW
12.1.13 TRANSPLANT BIOMEDICALS
TABLE 157 TRANSPLANT BIOMEDICALS: BUSINESS OVERVIEW
12.1.14 INSTITUT GEORGES LOPEZ
TABLE 158 INSTITUT GEORGES LOPEZ: BUSINESS OVERVIEW
12.1.15 GLOBAL TRANSPLANT SOLUTIONS
TABLE 159 GLOBAL TRANSPLANT SOLUTIONS: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 AVIONORD
TABLE 160 AVIONORD: BUSINESS OVERVIEW
12.2.2 ORGAN PRESERVATION SOLUTIONS LTD.
TABLE 161 ORGAN PRESERVATION SOLUTIONS LTD.: BUSINESS OVERVIEW
12.2.3 EBERS
TABLE 162 EBERS: BUSINESS OVERVIEW
12.2.4 S.A.L.F.
TABLE 163 S.A.L.F.: BUSINESS OVERVIEW
12.2.5 BIOCHEFA
TABLE 164 BIOCHEFA: BUSINESS OVERVIEW
12.2.6 VASCULAR PERFUSION SOLUTIONS, INC.
TABLE 165 VASCULAR PERFUSION SOLUTIONS, INC.: BUSINESS OVERVIEW
12.2.7 TX INNOVATIONS
TABLE 166 TX INNOVATIONS: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 210)
13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
This research study involved the use of comprehensive secondary sources; directories and databases such as D&B, Bloomberg Business, and Factiva; and white papers, annual reports, and companies’ house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the organ preservation market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side and demand side are detailed below. Industry experts such as CEOs, presidents, vice presidents, directors, marketing directors, marketing managers, and related executives from various key companies and organizations in the organ preservation industry were interviewed to obtain and verify both the qualitative and quantitative aspects of this research study. A robust primary research methodology has been adopted to validate the contents of the report and fill in the gaps.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by solution, technique, organ type, end user, and region).
After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Growth opportunities and latent adjacency in Organ Preservation Market
Interest in the organ preservation market, specifically organ preservation solutions
We have an investigation at the University on Organ Preservation Market and we want to analyze if it has potential. Thank you